CE marked (manufacturer/distributor materials indicate CE conformity for Nucleofill range — verify certificate for specific SKU/batch).
Marketed as a professional medical device/biostimulant for use by qualified practitioners.
CE marked (manufacturer/distributor materials indicate CE conformity for Nucleofill range — verify certificate for specific SKU/batch).
Marketed as a professional medical device/biostimulant for use by qualified practitioners.
Polynucleotide Skin Booster (Periorbital / Eyes)
Description
Nucleofill Eyes (formerly marketed as Nucleofill Soft Plus) is a sterile polynucleotide (sodium DNA) gel specifically formulated for periorbital rejuvenation. The product is supplied as a 2.0 mL prefilled syringe containing 15 mg polynucleotides (7.5 mg/mL). It is intended to improve dermo-epidermal skin quality, stimulate microcirculation and vascularity, support deep tissue regeneration and hydration, and reduce under-eye dark circles, fine lines and tear-trough hollows when administered by trained professionals.
Bnefits
Improves periorbital skin quality and reduces fine wrinkles by stimulating fibroblasts and collagen production.
Enhances microcirculation and vascularity—may reduce under-eye puffiness and dark circles over time.
Supports deep tissue regeneration and redistribution of adipose tissue in hypotrophic areas.
Provides long-lasting hydration of the extracellular matrix and improves skin texture.
Formulated specifically for delicate eye area with low molecular-weight polynucleotides for tissue integration.
Indications
Dark circles and periorbital hyperpigmentation
Tear-trough hollows and under-eye hollowness (as a biostimulatory adjunct)
Fine periorbital lines and micro-wrinkles
Periorbital skin revitalisation and hydration
Composition
Polynucleotide gel — 15 mg per 2.0 mL syringe (7.5 mg/mL)
Purified polynucleotide fragments (reported molecular weight ~50–100 kDa for this variant)
Sterile isotonic aqueous vehicle (full INCI/IFU available from manufacturer/distributor)
For professional use only — to be administered by trained healthcare practitioners experienced in periorbital injections.
Inject intradermally or superficially into the periorbital/tear-trough area using microdroplet, linear or point injection techniques per IFU and clinician judgement.
Observe aseptic technique and local aftercare guidance; avoid rubbing, heat exposure or strenuous exercise for 24–48 hours post-procedure.
Contraindications
Active infection or inflammation at the intended injection site
Known hypersensitivity to any component of the product
Pregnancy and breastfeeding (use only after clinician risk–benefit assessment and per local guidance)
Severe autoimmune disease or uncontrolled systemic illness (assess case-by-case)
Adverse Effects
Common (usually transient): local erythema, swelling, bruising, tenderness, small papules or nodularity at injection sites.
Less common/rare: infection, persistent nodules, hypersensitivity or allergic reactions.
Technique-related complications (e.g., vascular compromise) are possible — appropriate technique and emergency measures should be available.
Storage Conditions
Store in original packaging at room temperature as specified by manufacturer/distributor (avoid freezing and excessive heat).
Protect from direct sunlight and keep out of reach of children.
Check batch IFU for precise storage temperature and shelf-life/expiry information.
Duration
Progressive improvements commonly seen over weeks; longevity varies by patient and protocol \u2014 maintenance treatments typically recommended (clinic protocols vary).
Onset
Gradual \u2014 vascular and regenerative effects are often reported within ~30 days, with progressive improvement thereafter; immediate hydration/skin feel may be noticeable sooner.
